Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation from FDA

Shares of Intercept Pharmaceuticals Inc. (ICPT) were up +57.31 or +33.58 percent to $228.00 per share in pre-market trading on Thursday, after the company announced late yesterday its investigational product, obeticholic acid (OCA) had received “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treating patients with nonalcoholic steatohepatitis (NASH). Intercept Read the full article... Read the rest of Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation from FDA at InvestorGuide.com .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.